Real-world dose de-escalation of teclistamab in patients with R/R myeloma

Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, discusses real-world dose de-escalation of teclistamab in patients with relapsed/refractory (R/R) multiple myeloma (MM). While the MajesTEC-1 trial (NCT04557098) demonstrated the efficacy of teclistamab, it also highlighted a high risk of infection. Patients at Dr Usmani’s center who underwent dose de-escalation after three treatment cycles maintained a sustained response at six months, indicating this was an effective strategy to mitigate infection risk. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.